Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab PK and Safety in Healthy Chinese Subjects
NCT04362410Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2020
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tezepelumab in asthma (4 arms), sponsored by AstraZeneca. Primary endpoints: Area under the serum concentration versus time curve from time zero to Infinity at Day 113, Area under the serum concentration versus time curve from time zero to the last quantifiable concentration at Day 113 and 5 more. Started May 2020; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04362410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362410.